EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research

被引：136

作者：

Dong, Rui-Fang ^{[1
,2
]}

Zhu, Miao-Lin ^{[3
]}

Liu, Ming-Ming ^{[1
,2
]}

Xu, Yi-Ting ^{[1
,2
]}

Yuan, Liu-Liu ^{[1
,2
]}

Bian, Jing ^{[1
,2
]}

Xia, Yuan-Zheng ^{[1
,2
,4
]}

Kong, Ling-Yi ^{[1
,2
]}

机构：

[1] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China

[2] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China

[3] Jiangsu Canc Hosp, Dept Pathol, Nanjing 210009, Peoples R China

[4] Guangxi Med Univ, Minist Educ, Key Lab High Incidence Tumour Prevent & Treatment, Nanning 530021, Peoples R China

来源：

PHARMACOLOGICAL RESEARCH | 2021年 / 167卷

基金：

中国国家自然科学基金;

关键词：

EGFR mutations; NSCLC; EGFR-TKI resistance; Overcoming drug resistance; Future development; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; AFATINIB PLUS CETUXIMAB; EXON; 20; INSERTIONS; ACQUIRED-RESISTANCE; T790M MUTATION; BISPECIFIC ANTIBODY; TUMOR-CELLS; ERLOTINIB RESISTANCE; PROTEIN-DEGRADATION;

D O I：

10.1016/j.phrs.2021.105583

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) is a well-recognized and effective target for NSCLC therapies, targeted EGFR therapy with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has achieved ideal clinical efficacy in recent years. Unfortunately, resistance to EGFR-TKIs inevitably occurs due to various mechanisms after a period of therapy. EGFR mutations, such as T790M and C797S, are the most common mechanism of EGFR-TKI resistance. Here, we discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates.

引用

页数：18

共 177 条

[11] Studying clonal dynamics in response to cancer therapy using high-complexity barcoding [J].

Bhang, Hyo-eun C. ;

Ruddy, David A. ;

Radhakrishna, Viveksagar Krishnamurthy ;

Caushi, Justina X. ;

Zhao, Rui ;

Hims, Matthew M. ;

Singh, Angad P. ;

Kao, Iris ;

Rakiec, Daniel ;

Shaw, Pamela ;

Balak, Marissa ;

Raza, Alina ;

Ackley, Elizabeth ;

Keen, Nicholas ;

Schlabach, Michael R. ;

Palmer, Michael ;

Leary, Rebecca J. ;

Chiang, Derek Y. ;

Sellers, William R. ;

Michor, Franziska ;

Cooke, Vesselina G. ;

Korn, Joshua M. ;

Stegmeier, Frank .

NATURE MEDICINE, 2015, 21 (05) :440-U207

[12] The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study [J].

Burslem, George M. ;

Smith, Blake E. ;

Lai, Ashton C. ;

Jaime-Figueroa, Saul ;

McQuaid, Daniel C. ;

Bondeson, Daniel P. ;

Toure, Momar ;

Dong, Hanqing ;

Qian, Yimin ;

Wang, Jing ;

Crew, Andrew P. ;

Hines, John ;

Crews, Craig M. .

CELL CHEMICAL BIOLOGY, 2018, 25 (01) :67-+

[13] L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib [J].

Callegari, D. ;

Ranaghan, K. E. ;

Woods, C. J. ;

Minari, R. ;

Tiseo, M. ;

Mor, M. ;

Mulholland, A. J. ;

Lodola, A. .

CHEMICAL SCIENCE, 2018, 9 (10) :2740-2749

[14] A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib [J].

Castellano, Gina M. ;

Aisner, Joseph ;

Burley, Stephen K. ;

Vallat, Brinda ;

Yu, Helena A. ;

Pine, Sharon R. ;

Ganesan, Shridar .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) :1982-1988

[15] Development of targeted protein degradation therapeutics [J].

Chamberlain, Philip P. ;

Hamann, Lawrence G. .

NATURE CHEMICAL BIOLOGY, 2019, 15 (10) :937-944

[16] PGAMgnam Style: A Glycolytic Switch Controls Biosynthesis [J].

Chaneton, Barbara ;

Gottlieb, Eyal .

CANCER CELL, 2012, 22 (05) :565-566

[17]

Chen Kai, 2017, J Thorac Oncol, V12, pe65, DOI 10.1016/j.jtho.2016.12.024

[18] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].

Chen, Nan ;

Fang, Wenfeng ;

Zhan, Jianhua ;

Hong, Shaodong ;

Tang, Yanna ;

Kang, Shiyang ;

Zhang, Yaxiong ;

He, Xiaobo ;

Zhou, Ting ;

Qin, Tao ;

Huang, Yan ;

Yi, Xianping ;

Zhang, Li .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923

[19] Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death [J].

Chen, Ping ;

Huang, Han-Peng ;

Wang, Yi ;

Jin, Jun ;

Long, Wei-Guo ;

Chen, Kan ;

Zhao, Xiao-Hui ;

Chen, Chen-Guo ;

Li, Jian .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)

[20] Non-small-cell lung cancers: a heterogeneous set of diseases [J].

Chen, Zhao ;

Fillmore, Christine M. ;

Hammerman, Peter S. ;

Kim, Carla F. ;

Wong, Kwok-Kin .

NATURE REVIEWS CANCER, 2014, 14 (08) :535-546

← 1 2 3 4 5 6 7 8 9 10 →